Tabitha M. Cooney, MD

Director, Stop & Shop Family Pediatric Neuro-Oncology Outcomes Clinic


Assistant Professor of Pediatrics, Harvard Medical School
Office Phone: 617-632-4551
Appointment Phone: 617-632-2680
Fax: 617-632-4897


Treatment Centers
Clinical Interests
Clinical trial design, Disparities, Immunotherapies, Novel therapies, Protocol development, Survivorship


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA  02215


Board Certifications
Pediatric Hematology-Oncology, 2017
Pediatrics, 2013
Lucile Packard Children's Hospital / Stanford University, Pediatric Hematology/Oncology, 2016
Lucile Packard Children's Hospital / Stanford University, Pediatric Neuro-Oncology, 2017
Children's Hospital & Research Center Oakland, Pediatrics, 2013
Medical School
University of South Florida Morsani College of Medicine, 2010
Dr. Cooney's research interests include early phase clinical trial development for pediatric central nervous system (CNS) tumors, developmental therapeutics, disparities, and diversity. She has presented her findings, including initial results from a Phase 1 trial in Panobinostat for children with diffuse intrinsic pontine glioma (DIPG) and a DIPG historical cohort, at international and national meetings. Dr. Cooney is actively involved in several pediatric brain tumor consortia, holds leadership committee positions in the Pediatric Neuro-Oncology Consortium (PNOC) and Response Assessment in Pediatric Neuro-Oncology (RAPNO), and is a rising leader in her field.

Video: Meet Tabitha M. Cooney, MD

Appointments & Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Clinical Trials

Search our wide range of clinical trials, including novel therapies, immunotherapy and personalized therapy.callout bg

Harvard Medical Affiliate

HMS Callout FAD 

As a teaching affiliate of Harvard Medical School, our physicians are passing on their expertise to the next generation of pediatric hematologists and oncologists.